GSK-Spero Utebzi OKd in the US for adults with complicated urinary tract infections

 

• First and only oral carbapenem antibiotic approved in the US 
• Approval based on PIVOT-PO trial demonstrating non-inferiority compared to intravenous treatment1 
• More than 3 million cases of cUTIs are treated annually in the US2 with up to a third of patients impacted by resistant infections3 
• https://us.gsk.com/en-us/media/press-releases/utebzi-tebipenem-pivoxil-approved-in-the-us-for-adults-with-complicated-urinary-tract-infections-cutis/